| Literature DB >> 31243301 |
Shivani Sharma1,2,3,4, Renato Aguilera5, JianYu Rao6,7,8,9, James K Gimzewski10,11,12.
Abstract
Palpable thyroid lesions are common, and although mostly benign, lethal malignant nodules do occur and may be difficult to differentiate. Here, we introduce the use of a piezoelectric system called Smart-touch fine needle (or STFN) mounted directly onto conventional biopsy needles, to evaluate abnormal tissues, through quantitative real-time measurements of variations in tissue stiffness as the needle penetrates tissue. Using well-characterized biomaterials of known stiffness and explanted animal tissue models, we first established experimental protocols for STFN measures on biological tissues, as well as optimized device design for high signal-to-noise ratio. Freshly excised patient thyroids with varying fibrotic and malignant potential revealed discrete variations in STFN based tissue stiffness/stiffness heterogeneity and correlated well with final histopathology. Our piezoelectric needle sensor reveals mechanical heterogeneity in thyroid tissue lesions and provides a foundation for the design of hand-held tools for the rapid, mechano-profiling of malignant lesions in vivo while performing fine needle aspiration (FNA).Entities:
Mesh:
Substances:
Year: 2019 PMID: 31243301 PMCID: PMC6594950 DOI: 10.1038/s41598-019-45730-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Experimental set-up for the smart-touch fine needle (STFN). (a) Optical image of the STFN device composed of a 25G fine needle, PLA polymer housing and connected to RG-58/U coaxial BNC cable. (b) Design schematic of housing attaches the needle to piezoelectric tube transducer and piezo-response measured through 20 AWG twisted pair Cu wire. The twisted pair is frayed to connect to the BNC. (c) An illustration shows the experimental connection diagram of STFN. (d) Schematic diagram of a cross-section of porcine kidney samples showing fibrous capsule, cortex and medulla regions. (e) An example of force versus needle displacement profile from STFN penetrating through the tubules of the kidney sample. Before the estimated point of contact (marked with a solid black arrow) between the needle and kidney tissue, the force observed was minimal. After the point of contact (solid black arrow), there is an elastic deformation due to fibrous capsule until an abrupt Hertzian penetration (broken black arrow) occurs. Subsequent deformation peaks occur (labeled L1 to 5) before full penetration at the point marked as exit (broken black arrow).
Figure 2Experimental workflow during the typical STFN measurements and distribution of tissue stiffness heterogeneity observed for thyroid carcinoma and the healthy thyroid. Following a standard operating procedure, samples were first prepared by attachment and orientation into quadrants, using (a) biocompatible sample holders with calibrated grids as illustrated schematically in (b). (c) An inked patient sample measured using STFN. Samples were later processed for standard tissue histology.
Figure 3Method for determining the presence and location of the nodules in ex vivo human thyroid samples- based on needle biomechanical response. a.i, Shows the characteristic STFN response for the initial point of contact between the needle and the tissue sample (solid black arrows), followed by penetration (marked by broken arrows) into non-tumor and tumor tissues shown in red and black curves respectively. Malignant specimens (black) show several broken arrows corresponding to secondary interfaces caused by tumors as corroborated by histology. Within the identified regions of interest (marked with * and ** for non-tumor and tumor samples respectively), heterogeneity of tissue stiffness is analyzed based on Equation 1 given in a(ii). (b,c) Show corresponding force-displacement curves from ROI for non-tumor (region marked with * in red curve in a.i), and tumor (region marked with ** in black curve in a.i) samples respectively. Representative ex vivo measurements of human thyroid following standardized operating procedures, show distinct responses between malignant and benign samples.
Statistical analysis of tumor variants. STFN data for 76 measurements are statistically analyzed according to their corresponding histology reports.
| No. | Age/sex | Clinical History | Cytological/Histology |
|---|---|---|---|
| 1 | 45/M | Papillary Thyroid Carcinoma 2.6 cm tumor | Positive for metastatic malignant cells |
| 2 | 52/M | Papillary Thyroid Carcinoma 1.2 cm pT3 pN0 | Positive for metastatic malignant cells |
| 3 | 64/M | Cystic Papillary Thyroid Carcinoma 0.8 cm | Positive for metastatic malignant cells |
| 4 | 47/F | Hyperthyroidism and Thyroid Goiter | Negative for malignancy, cyst lined follicular cells |
| 5 | 73/M | Papillary Thyroid Carcinoma 1.7 cm pT3 N1b | Positive for metastatic malignant cells |
| 6 | 29/F | Papillary Thyroid Carcinoma with Hashimoto thyroiditis 1.5 cm pT3 N1a | Positive for metastatic malignant cells |
| 7 | 64/M | Cystic Thyroid Goiter with Gout | Negative for malignancy, multinodular goiter |
| 8 | 23/F | Hyperparathyroidism post parathyroidectomy | Positive for metastatic malignant tall cells, papillary thyroid microcarcinoma pT3Nx |
| 9 | 33/M | Papillary Thyroid Carcinoma 1.1 cm | Positive for metastatic malignant tall cells |
| 10 | 68/M | Papillary Thyroid Carcinoma 4.5 cm | Positive for metastatic malignant cells |
| 11 | 49/F | Papillary Thyroid Carcinoma 1.6 cm | Positive for metastatic malignant cells |
| 12 | 69/M | Hashimoto thyroiditis 0.2 cm | Positive for metastatic malignant cells |
Variants of benign samples (Adenomatoid and Normal) show similar qualities while malignant samples (others) show drastic variability. Classification of each variant can be observed through their heterogeneous response using Principal Component Analysis.
Figure 4STFN based quantitative biomechanical analysis of patient thyroid tissue samples with corresponding representative histology. Corresponding data in (a,b), were obtained from one normal, one adenomatoid, four papillary, two cystic, three tall cell and two Hashimoto thyroiditis patients samples as described in Table 1. (a) Tissue stiffness heterogeneity (uM) and (b) tissue stiffness (mN/mm) evaluated for all thirteen patient samples studied. Data are stratified based on tissue variant types. Variants of benign thyroid samples (normal and adenomatoid) show similar biomechanical characteristics compared to malignant samples (others). (c) Histology data corresponding to each thyroid tissue variant represent (i) normal, (ii) adenomatoid, (iii) papillary of usual type, (iv) papillary carcinoma with cystic component, (v) tall cell variant, and (vi) Hashimoto disease respectively.